• 제목/요약/키워드: Ornithine transcarbamylase

검색결과 19건 처리시간 0.023초

신생아기 경련 및 의식저하를 주소로 내원한 Ornithine Transcarbamylase Deficiency 남아 1례 (A Case of Ornithine Transcarbamylase Deficiency in a Boy with Neonatal Seizure and Altered Mentality)

  • 임민지;송아리;이수연;박형두;조성윤;진동규
    • 대한유전성대사질환학회지
    • /
    • 제18권2호
    • /
    • pp.55-61
    • /
    • 2018
  • OTC 결핍증은 요소 회로 대사 질환 중 가장 흔한 질환으로, X연관 유전을 하며, 고암모니아 혈증, 의식저하, 구토, 경련 등을 주증상으로 하여 나타난다. 본 증례에서는 경련 및 의식 저하로 발견된 고암모니아 혈증 및 저칼슘혈증에 대한 치료로 칼슘 보충 및 저단백섭취, sodium benzoate, phenylbutyrate sodium, L-arginine 복용 및 CRRT를 시행하여 증상을 경감시키고, 생화학적 검사 및 Targeted exome sequencing을 통하여 OTC 결핍증을 확진함으로서 신경학적 예후에 대비하도록 하였다. 이로서 현재까지 비교적 양호한 경과를 보이기에 이 증례를 보고하는 바이다.

  • PDF

Enhancement of Erythropoietin Production from Chinese Hamster Ovary(CHO) Cells by Introduction of the Urea Cycle Enzymes, Carbamoyl Phosphate Synthetase I and Ornithine Transcarbamylase

  • Kim, Na-Young;Lee, Yun-Jeong;Kim, Hyung-Jin;Choi, Jung-Ho;Kim, Jung-Kwon;Chang, Kern-Hee;Kim, Jung-Hoe;Kim, Hong-Jin
    • Journal of Microbiology and Biotechnology
    • /
    • 제14권4호
    • /
    • pp.844-851
    • /
    • 2004
  • Efficient mammalian erythropoietin (EPO)-expression systems are required for therapeutic applications. The accumulation of ammonia is a major problem in the production of recombinant proteins in cultured animal cells. To counter this problem we introduced the first two genes of the urea cycle, carbamoyl phosphate synthetase (CPSI) and ornithine transcarbamylase (OTC), into IBE Chinese Hamster Ovary (CHO) cells by stable transfection. The resulting cell line, CO5, had a higher growth rate and accumulated less ammonia per cell than the parental cell line, IBE. In addition, it produced 2 times more EPO than the parent, and the purified EPO contained a higher proportion of acidic isoforms with approximately 15% more sialic acid.

단일 유전자 이상에 대한 착상전 유전진단을 위한 단일 세포 PCR 방법의 신뢰성 (Reliability of the Single Cell PCR analysis for Preimplantation Genetic Diagnosis of Single Gene Disorders)

  • 최혜원;이형송;임천규;궁미경;강인수;전진현
    • Clinical and Experimental Reproductive Medicine
    • /
    • 제32권4호
    • /
    • pp.293-300
    • /
    • 2005
  • 연구목적: 단일 유전자 이상에 대한 착상전 유전진단을 성공적으로 시행하기 위해서는 효과적이고 신뢰도가 높은 PCR 방법의 확립이 중요하다. 본 연구에서는 alkaline lysis와 duplex nested PCR 방법을 단일 림프구와 할구의 유전자 분석에 적용하여 그 효용성을 확인하고자 하였다. 재료 및 방법: 단일 유전자의 이상이 확인된 Duchenne muscular dystrophy (DMD), ornithine transcarbamylase (OTC) 결핍증과 epidermolysis bullosa (EB) 가계의 대상자들에서 채취한 단일 림프구와 공여 받은 배아의 할구를 이용하여 각각 PCR, restriction fragment length polymorphism (RFLP)와 direct DNA sequencing 분석을 시행하였다. 이러한 분석에서 유전자 증폭률 (amplification rate)과 두개의 allele 중에서 하나의 allele이 증폭되지 않는 allele drop-out (ADO) 빈도에 대해 살펴보았다. 결 과: 단일 림프구와 할구를 이용한 PCR 방법의 유전자 증폭률은 DMD에서 91.1%와 81.8%, OTC 결핍증에서 96.0%와 78.1%, EB에서 91.3%와 90.0%를 각각 나타냈으며, ADO 빈도는 OTC 결핍증에서 13.3%, EB에서 16.8%로 관찰되었다. 결 론: 본 연구에서 적용한 alkaline lysis와 duplex nested PCR 방법은 단일 유전자에 대한 착상전 유전진단에 성공적으로 적용할 수 있는 방법으로 생각되며, ADO 빈도를 최소화할 수 있는 효율적인 방법의 개발에 대한 지속적인 연구가 필요하다.

아데노바이러스 유전자치료제의 독성 (Toxicity of the Adenoviral Vector Mediated Gene Therapy)

  • 정인재
    • Environmental Analysis Health and Toxicology
    • /
    • 제24권1호
    • /
    • pp.71-77
    • /
    • 2009
  • Adenoviral vector(AdV) has been the most widely used viral vector for delivering an exogenous therapeutic gene to human. As of this date, more clinical trials utilize recombinant AdV to treat cancer and monogenic inherited disease as well as vaccine applications. However, the number of clinical trials had dropped markedly following the tragic death of a patient ongoing an AdV therapy for the treatment of an ornithine transcarbamylase deficiency(OTCD). This review is an attempt to provide the information on toxicity generated by AdVmediated gene transfer. It would serve as a sobering reality to researchers and clinicians exploring the use of AdV, as to the complications involved in human application.

Successful treatment of a child with citrullinemia

  • Lee, Key-Hyoung;Park, Moon-Sung;Hahn, Si-Hoon
    • Journal of Genetic Medicine
    • /
    • 제1권1호
    • /
    • pp.5-10
    • /
    • 1997
  • The amino acids formed by degradation of proteins ingested produce ammonia. The ammonia which is broken down and excreted as urea through a process known as the Klebs-Hensleit cycle or the urea cycle (Rezvani, 1995). The urea cycle consists of five enzymes necessary for the synthesis of carbamyl phosphate, citrulline, argininosuccinate, arginine, and urea: carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), argininosuccinate synthetase (AS), argininosuccinate lyase (AL), and arginase (ARG) (Lloyd, 1992). Congenital deficiencies of the enzymes involved in the urea cycle are diseases that are almost fatal without treatment, showing symptoms like vomiting, lethargy, dyspnea, and coma due to hyperammonemia coming from the accumulation of ammonia and metabolic precursors resulting from the deficiency of one of these enzymes (Batshaw and Brusilow, 1983). Among these, the disease manifested by the congenital deficiency of argininosuccinate synthetase (AS) which is associated with the formation of argininosuccinate in citrulline is called argininosuccinate synthetase deficiency or citrullinemia. There have been two reports on this so far in Korea; one in July 1987 by Kim et al. and the other by Park et al. in 1995. We are to report a case of successful treatment of a child with citrullinemia who was transferred to our hospital due to dyspnea, lethargy, feeding difficulties, convulsions and cyanosis together with some document studies related to this case.

  • PDF

Clinical Manifestations of Inborn Errors of the Urea Cycle and Related Metabolic Disorders during Childhood

  • Endo, Fumio;Matsuura, Toshinobu;Yanagita, Kaede;Matsuda, Ichiro
    • 대한유전성대사질환학회지
    • /
    • 제5권1호
    • /
    • pp.76-87
    • /
    • 2005
  • Various disorders cause hyperammonemia during childhood. Amongthem are those caused by inherited defects in urea synthesis and related metabolic pathways. These disorders can be grouped into two types: disorders of the enzymes that comprise the urea cycle, and disorders of the transporters or metabolites of theamino acids related to the urea cycle. Principal clinical features of these disorders are caused by elevated levels of blood ammonium. Additional disease-specific symptoms are related to the particular metabolic defect. These specific clinical manifestations are often due to an excess or lack of specific amino acids. Treatment of urea cycle disorders and related metabolic diseases consists of nutritional restriction of proteins, administration of specific amino acids, and use of alternative pathways for discarding excess nitrogen. Although combinations of these treatments are extensively employed, the prognosis of severe cases remains unsatisfactory. Liver transplantation is one alternative for which a better prognosis is reported.

  • PDF

Clinical Features, Response to Treatment, Prognosis, and Molecular Characterization in Korean Patients with Inherited Urea Cycle Defects

  • Yoo, Han-Wook;Kim, Gu-Hwan;Seo, Eul-Ju
    • 대한유전성대사질환학회지
    • /
    • 제2권1호
    • /
    • pp.77-79
    • /
    • 2002
  • The urea cycle, consisting of a series of six enzymatic reactions, plays key roles to prevent the accumulation of toxic nitrogenous compound and synthesize arginine de novo. Five well characterized diseases have been described, resulting from an enzymatic defect in the biosynthesis of one of the normally expressed enzyme. This presentation will focus on two representative diseases; ornithine transcarbamylase(OTC) deficiency and citrullinemia(argininosuccinate synthetase deficiency). OTC deficiency is one of the most common inborn error of urea cycle, which is inherited in X-linked manner. We identified 17 different mutations in 20 unrelated Korean patients with OTC deficiency; L9X, R26P, R26X, T44I, R92X, G100R, R141Q, G195R, M205T, H214Y, D249G, R277W, F281S, 853 del C, R320X, V323M and 10 bp del at nt. 796-805. These mutations occur at well conserved nucleotide sequences across species or CpG hot spot. The L9X and R26X lead to the disruption of leader sequences, required for directing mitochondrial localization of the OTC precursor. Their phenotypes are severe, and neonatal onset. The G100R, R277W and V323M mutations were uniquely identified in patients with late onset OTC deficiency. The other genotypes are associated with neonatal onset. Out of 20 patients with OTC deficiency, only 6 patients are alive; two were liver transplanted, and normal in growth and development at 2, 4 years after transplantation respectively. Citrullinemia is an autosomal recessive disease, caused by the mutations in the argininosuccinate synthetase(ASS) gene. We identified in 3 major mutations in 11 unrelated Korean patients with citrullinemia; G324S, $IVS6^{-2}$ A to G, and 67 bp ins at nt 1125-1126. Among these, the 67 base pair insertion mutation is novel. The allele frequency of each mutation is; G324S(45%), IVS6-2 A to G(32%), and 67 base pair insertion(14%). All patients are diagnosed at neonatal or infantile age. Interestingly, two patients presented with stroke like episode. Out of 11 patients, 5 patients died. Among 6 patients alive, one patient was successfully liver transplanted.

  • PDF

요소회로대사 질환 환자들의 장기적인 임상 경과에 대한 단일 기관 경험 (Long-term Clinical Consequences in Patients with Urea Cycle Disorders in Korea: A Single-center Experience)

  • 이준;김민지;유석동;윤주영;김유미;전종근
    • 대한유전성대사질환학회지
    • /
    • 제21권1호
    • /
    • pp.15-21
    • /
    • 2021
  • 목적: 요소회로대사 질환은 선천성 대사이상질환으로, 요소 회로 각 단계의 특정 효소의 결핍에 따라 다양한 질환과 임상적 증상이 나타난다. 본 연구의 목적은 요소회로대사 질환의 다양한 종류에 따른 장기적 임상 경과를 조사하는 것이다. 방법: 부산대학교 어린이병원에 등록된 22명의 요소회로대사 질환 환자들의 임상적 양상과 생화학적, 유전학적 검사 결과들을 포함한 의무기록을 후향적으로 조사하였다. 결과: 본 연구에서 진단된 요소회로대사 질환은, OTCD 10명(45.5%), ASSD 6명(27.3%), CPS1D 3명, HHHS 2명 ARG1D 1명으로 확인되었다. 진단 시 평균연령은 32.7±66.2개월(범위 0.1-228.0개월) 이었다. 요소회로대사 질환 환자 8명(36.4%)에서 성장 장애가 동반되었다. 또한 요소회로대사 질환 환자11명(50%)에서는 신경학적 후유증이 관찰되었다. 분자유전학적 분석 결과 새로운 돌연변이 14개를 포함해 37개의 서로 다른 돌연변이 유형(과오돌연변이 14개, 넌센스 6개, 결실변이 6개, 스플라이싱변이 6개, 결실삽입변이 3개, 삽입변이 1개, 중복변이 1개)이 확인됐다. 진행성 성장 장애와 나쁜 신경학적 결과는 혈장 이소루이신과 루이신 농도와 각각 관련이 있었다. 결론: 단백의 제한과 같은 조치나 과다한 질소를 제거하는 약제의 복용에도 불구하고, 요소회로대사 질환의 예후는 아직까지 만족스럽지 못하다. 가지사슬아미노산의 보충이 요소회로대사 질환 환자들의 성장부전과, 대사성 위기 또는 신경학적 예후에 효과를 보일지에 관해서는 전향적인 추가 연구가 필요하겠다.